https://myci975inhibitor.com/c....linical-results-and-
The placebo had been coordinated to serelaxin on appearance and administration protocol to create and continue maintaining blinding. The main endpoint ended up being the alteration from baseline in fasting HVPG after 2 h of peripheral i.v. serelaxin infusion (80 μg/kg/day for 60 min accompanied by 30 μg/kg/day for at least 60 min). Additional endpoints included the alteration from baseline in hepatic circulation and systemic haemodynamics (cardiac index, sysorded 12 adverse events in 7 indiv
Like
Comment
Share
